Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.
Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Lüscher TF, Landmesser U.
Besler C, et al. Among authors: von eckardstein a.
J Clin Invest. 2011 Jul;121(7):2693-708. doi: 10.1172/JCI42946. Epub 2011 Jun 23.
J Clin Invest. 2011.
PMID: 21701070
Free PMC article.